Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
609A + Doxorubicin in Soft Tissue Sarcoma
NCT05138146Phase 2Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of 609A in soft tissue sarcoma (STS), sponsored by 3S Guojian Pharmaceutical. Status: unknown.
02
Drugs
609A
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05138146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138146.